TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers at Michigan Medicine report that experimental compound DT-109 reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal studies. The work links the benefit to reduced harmful gut bacteria, lower intestinal ammonia and a stronger gut barrier; the findings do not establish that the drug works in people.
Experimental compound DT-109 reversed MASH in animal studies by reducing harmful gut bacteria and helping restore the intestinal barrier, according to research from Michigan Medicine published in The Journal of Clinical Investigation. The findings point to a possible way to limit liver damage through the gut, but do not show that DT-109 is effective or safe in people.
The researchers linked the drug’s effects to a process involving Clostridium perfringens, a gut bacterium that produces ammonia. In the study, excessive growth of the bacterium and rising ammonia levels were associated with damage to the intestine’s protective lining. A weakened barrier can allow microbial products to enter the bloodstream and reach the liver, where they may promote inflammation.
In experiments involving mice and nonhuman primates, DT-109 reduced levels of the bacterium and intestinal ammonia. The team reported that these changes helped strengthen the gut lining and limit the movement of potentially harmful microbial products. In the nonhuman primates, the researchers also observed reduced liver inflammation and less severe MASH.
The study builds on earlier animal research in which DT-109 improved MASH, while examining how the compound may work. The new findings describe a proposed chain linking gut bacteria, intestinal barrier damage and liver inflammation. They do not establish that this mechanism is the only cause of MASH, or that the same effects will occur in humans.
A Gut-Based Route to Liver Protection
MASH is a serious form of fatty liver disease in which fat accumulation is accompanied by inflammation and cell damage. It can progress to cirrhosis, liver cancer or liver failure. The source report estimates that MASH affects about 7% of the world’s population, while describing effective treatment options as limited.
Most directly, the study offers a potential treatment strategy aimed at processes that may contribute to liver injury, rather than treating the liver in isolation. If the mechanism proves relevant in people, influencing the gut-liver connection could provide another avenue for addressing inflammation. At present, however, the reported benefits are preclinical; they are not evidence that patients can use DT-109 or expect a clinical benefit.
liver health supplements for fatty liver
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Gut Changes May Affect the Liver
The liver receives substances absorbed from the digestive tract, creating a biological connection commonly called the gut-liver axis. The research team says microbial products crossing a damaged intestinal lining may contribute to inflammation in the liver. The study describes excessive activation of CD8+ T cells, immune cells that can contribute to inflammatory damage when overactive, as part of this process.
DT-109 is a glycine-based tripeptide, a small molecule made of three amino acids. The latest work investigates how it may influence the gut environment and barrier function. The researchers also point to prior animal studies of DT-109 involving artery plaque formation and vascular calcification, but those results do not establish treatment benefits for cardiovascular disease in people.
“We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression.”
— Eugene Chen, senior study author and professor of cardiovascular medicine at the University of Michigan Medical School
As an affiliate, we earn on qualifying purchases.
Human Evidence Is Still Missing
The reported results come from animal models, not clinical trials in people. The source material does not provide human safety data, an effective human dose, trial results or a timeline for testing DT-109 in patients. It is also not clear whether the effects seen in the animals would translate to people with MASH or how durable the reported improvements would be.
The findings support a proposed mechanism, but they do not establish that gut bacteria or ammonia account for all MASH cases. The study also does not show that DT-109 reverses advanced liver scarring, prevents liver cancer or treats liver failure. Those outcomes would require separate evidence.
As an affiliate, we earn on qualifying purchases.
Clinical Testing Would Be Needed
The immediate next step toward assessing DT-109 as a treatment would be further research, including studies that establish safety and whether the animal findings can be reproduced in people. The source report does not identify a planned or ongoing human trial, so the timing and design of any clinical testing remain unknown.
Until human evidence is available, DT-109 should be understood as an experimental compound rather than an established MASH treatment. Researchers would need to report clinical outcomes and safety data before its potential role in patient care could be assessed.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is DT-109?
DT-109 is an experimental glycine-based tripeptide studied for its effects on gut conditions and MASH in animals. The report does not describe it as an approved treatment.
Did DT-109 reverse fatty liver disease in people?
No human results are reported. The study found improvements in animal models, including mice and nonhuman primates; whether the findings apply to people is unknown.
How might the drug affect the liver?
Researchers report that DT-109 reduced Clostridium perfringens and intestinal ammonia, helping protect the gut lining. They say this may limit microbial products reaching the liver and contributing to inflammation.
When could DT-109 become available?
The source material gives no timeline for human trials or possible availability. Further testing, including human safety and effectiveness studies, would be needed before its use in patient care could be assessed.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
